Brecanavir
Jump to navigation
Jump to search
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C33H41N3O10S2 |
Molar mass | 703.82 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Brecanavir (INN; codenamed GW640385) is a protease inhibitor which has been studied for the treatment of HIV.[1]
In December 2006, its developer, GlaxoSmithKline discontinued further development because of insurmountable issues regarding formulation.[2]
See also
References
- ^ Hazen R, Harvey R, Ferris R, et al. (September 2007). "In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV". Antimicrob. Agents Chemother. 51 (9): 3147–54. doi:10.1128/AAC.00401-07. PMC 2043237. PMID 17620375.
- ^ "GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385)" (Press release). GlaxoSmithKline. 2006-12-18. Archived from the original on 2008-12-03. Retrieved 2008-06-11.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Articles with changed CASNo identifier
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Abandoned drugs
- Secondary alcohols
- Benzodioxoles
- Carbamates
- Furofurans
- HIV protease inhibitors
- Thiazoles
- Isobutyl compounds
- All stub articles
- Antiinfective agent stubs